Vistagen receives US patent for nasal spray to treat migraine

Vistagen announced that the U.S. Patent and Trademark Office granted a patent for the company’s investigational pherine PH80 nasal spray for the treatment of migraine.

According to a Vistagen press release, PH80 is designed with a uniquely formulated rapid-onset mechanism that does not require systemic exposure to produce an effect. PH80 nasal spray works by engaging neural impulses in the olfactory bulb transmitted by pathways that rapidly affect brain function, including the amygdala and hypothalamus.

Vistagen’s recently completed acquisition of Pherin Pharmaceuticals resulted in the full ownership of intellectual property rights worldwide to five pherine drug candidates, including the newly issued PH80 patent, the release stated.

Vistagen additionally revealed the patent will be in effect until at least 2040.